GET DAILY SIGNALSSchrödinger (SDGR): Assessing the Path to a $33 Price Target
Key Takeaways
- The central target of $33 is the average of the verified analyst price targets that sit above the current share price, not a published Street consensus.
- Five current targets were reviewed, spanning roughly $29 to $36; the overall mean of all five is about $32.
- The latest verified price of about $29.82 leaves roughly 11% upside to the $33 central target, a modest move.
- Strongest supports are accelerating software demand, a fourth-quarter guidance raise, and a wave of analyst target increases tied to AI-driven drug discovery.
- Biggest risks are volatile collaboration revenue, ongoing operating losses, competition, and a valuation that already prices in high expectations.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages to track developments as they unfold.
- You can also monitor automated, AI-driven stock ideas through Trending AI Robots.
Analyst Price Targets and Consensus View
Five credible, current analyst price targets were reviewed. Because the arithmetic mean of all five (about $32.40) sits only about 7% above the latest price, the central target used here is the average of the targets that are above the current price, per a minimum-distance rule. Those four above-price targets average $33.25, rounded to $33. For context, the overall mean of all five valid targets is roughly $32, and the full range runs from $29 to $36.
The targets diverge on conviction. TD Cowen (Buy, $36, raised from $31) and BMO Capital (Outperform, $35) are the most bullish, citing a strong software outlook and progress toward hosted contracts. KeyBanc (Overweight, $32) points to interest in AI-driven drug discovery. On the cautious side, UBS (Neutral, $30) and Morgan Stanley (Equal Weight, $29, raised from $17) acknowledge improved software traction but flag elevated expectations and limited near-term catalysts. This spread—bullish software momentum versus cautious valuation—explains the relatively wide range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock around $29.82 at the November 6, 2026 close, reaching $33 implies roughly 11% upside, a modest move by equity-market standards. The path would most likely run through continued strength in the software business. Schrödinger recently reported a fourth-quarter beat in annual contract value (ACV) and raised full-year 2026 guidance at the midpoint, while a structure milestone supported third-quarter revenue. Because the collaboration segment is inherently lumpy, quarter-to-quarter results can swing sharply even as the recurring software base grows.
What Could Support a Move Toward the Target
- Software momentum: A 4% ACV beat and a guidance raise signal growing traction for the platform.
- AI drug-discovery theme: Several analysts cited rising interest in AI-driven research as a reason for lifting targets.
- Strategic partnerships: Collaborations with major pharmaceutical partners, including Novartis and Eli Lilly, validate the platform's commercial relevance.
- Analyst revisions: Multiple firms raised targets in October and November 2026, a generally constructive signal.
- Expanding applications: Research extending the platform into areas such as battery electrolytes broadens the addressable market.
What Could Prevent the Target From Being Reached
- Lumpy collaboration revenue: Discovery revenue tied to milestones and collaborations can swing quarter to quarter.
- Ongoing losses: The company has reported losses in most recent years as it invests in research and development.
- Elevated expectations: Morgan Stanley and UBS caution that much of the good news may already be reflected in the price.
- Valuation compression: A price-to-sales multiple near 6.9x leaves little room if growth disappoints.
- Competition and clinical risk: Computational drug-discovery rivals and the uncertain outcome of internal pipeline programs remain headwinds.
Technical Levels and Market Structure
The stock's climb from the mid-teens to near $30 reflects a powerful momentum move that has carried shares above several prior average analyst targets. The round-number $30 level now serves as a psychological pivot: holding above it would keep the near-term uptrend intact, while slipping back below could signal that the rally has stalled. Beyond that, durable support and resistance zones are less clearly defined after such a rapid advance, so investors should treat current technicals as momentum-driven rather than anchored in long-standing price history.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different assumptions and timelines. Key items to watch include the next quarterly earnings release and any updates to guidance, further analyst target revisions, new partnership or licensing announcements, and data from the internal clinical pipeline. Broader conditions in the biotech and healthcare-IT sectors—especially funding and AI-related sentiment—will also influence how the stock trades relative to the $33 target. From what I see, this is important because sustained momentum in the core platform will determine whether the target holds.
Exploring AI Daily Buy/Sell Signals
In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to monitor stocks like SDGR by applying artificial intelligence to thousands of securities. The system generates Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI analysis, which can complement fundamental work when tracking opportunities or shifts in trend. I find this layer helpful for adding structure to ongoing research without replacing deeper analysis.
Final Assessment
The $33 central target—an average of the analyst targets above the current price—requires roughly an 11% advance from about $29.82, a modest but not automatic move. The case for it rests on strengthening software demand, a guidance raise, and a favorable AI drug-discovery narrative that has driven a cluster of target increases. The counterargument is equally clear: collaboration revenue is volatile, the company remains unprofitable, and some analysts warn that expectations already run high, with the full analyst range stretching from $29 to $36. The most important signals ahead will be sustained software growth, guidance follow-through, and any evidence that the platform's momentum extends beyond a single strong quarter. I’m watching this closely as the next earnings cycle unfolds.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SDGR's Stochastic Oscillator entering overbought zone
The Stochastic Oscillator for SDGR moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SDGR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 24 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
SDGR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SDGR as a result. In 70 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for SDGR just turned positive on October 28, 2026. Looking at past instances where SDGR's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
SDGR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SDGR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDGR advanced for three days, in 215 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 137 of 187 cases where SDGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.781) is normal, around the industry mean (4.477). SDGR has a moderately low P/E Ratio (-40.849) as compared to the industry average of (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.835) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SDGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of chemical simulation software solutions to pharmaceutical industry.
Industry ServicestotheHealthIndustry
Advertisement